When to Contact Your Healthcare Provider While most side effects are manageable, certain symptoms warrant immediate medical evaluation: Severe, persistent abdominal pain (especially if radiating to your back)may indicate pancreatitis Right upper abdominal pain, fever, or yellowing of skin/eyes may indicate gallbladder problems Persistent vomiting leading to dehydration or decreased urination/swelling (possible acute kidney injury) Visual changes or symptoms of diabetic retinopathy worsening Signs of hypoglycemia if taking semaglutide with insulin or sulfonylureas (shakiness, confusion, rapid heartbeat) Rash, swelling, or trouble breathing may indicate hypersensitivity reaction Symptoms of thyroid tumors (neck mass, difficulty swallowing, persistent hoarseness)though extremely rare Practical Management Tips To optimize your early experience with semaglutide: Inject at the same time each week for consistency Stay well-hydrated, especially if experiencing GI symptoms Monitor blood glucose if diabetic, as you may need adjustments to other diabetes medications Keep a symptom diary to track patterns and discuss with your provider Don't expect dramatic changes immediatelypatience is essential for successful treatment Important: If you're pregnant, planning pregnancy, or breastfeeding, discuss with your doctor
The American Diabetes Association recommends A1C testing every 3 months when therapy changes or targets are not met
Be prepared to work with your doctor on a prior authorization request.
[1] [6] Beyond its glucose-lowering effects, semaglutide has been associated with modest improvements in several cardiovascular risk factors, including modest blood pressure reduction and weight loss
It can also treat obstructive sleep apnea (OSA) in people with obesity
Side-by-side comparison Factor Receptor targets Semaglutide GLP-1 only Tirzepatide GLP-1 + GIP Retatrutide GLP-1 + GIP + glucagon Liraglutide GLP-1 only Factor Half-life Semaglutide ~7 days Tirzepatide ~5 days Retatrutide ~6 days Liraglutide ~13 hours Factor Dosing frequency Semaglutide Once weekly Tirzepatide Once weekly Retatrutide Once weekly Liraglutide Once daily Factor Max studied dose Semaglutide 2.4 mg/week (SubQ)
